group A,C meningococcal conjugate vaccine

The group A,C meningococcal conjugate vaccine is a bivalent vaccine designed to prevent invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A and C. It consists of purified capsular polysaccharides from these two serogroups, each chemically conjugated to a carrier protein (such as tetanus toxoid or CRM197). This conjugation converts the T-cell independent polysaccharide antigens into T-cell dependent antigens, which significantly enhances immunogenicity, particularly in infants and young children, and promotes long-term immunological memory. The specific product developed by the Wuhan Institute of Biological Products (a subsidiary of Sinopharm/CNBG) has been evaluated in clinical trials in China to demonstrate safety and immunogenicity compared to existing polysaccharide and conjugate vaccines. It is typically administered as an intramuscular injection and is part of the routine immunization schedule in regions where these serogroups are prevalent.

Other names

A,C meningococcal conjugate vaccinemeningococcal group A and C conjugate vaccinebivalent meningococcal conjugate vaccine (groups A and C)lyophilized group A,C meningococcal conjugate vaccine